The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 17, 2023
Filed:
Mar. 30, 2022
Applicant:
Kowa Company, Ltd., Chuo-ku, JP;
Inventors:
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/423 (2006.01); A61K 31/34 (2006.01); A61K 31/4152 (2006.01); A61K 31/427 (2006.01); A61K 31/4353 (2006.01); A61K 31/4402 (2006.01); A61K 31/4433 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/513 (2006.01); A61K 31/7034 (2006.01); A61K 38/13 (2006.01); A61P 3/06 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/423 (2013.01); A61K 31/34 (2013.01); A61K 31/4152 (2013.01); A61K 31/427 (2013.01); A61K 31/4353 (2013.01); A61K 31/4402 (2013.01); A61K 31/4433 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 31/7034 (2013.01); A61K 31/7048 (2013.01); A61K 38/13 (2013.01); A61P 3/06 (2018.01); A61K 45/06 (2013.01);
Abstract
To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.